{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:47:45Z","timestamp":1793497665103,"version":"4.5.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K07906"],"award-info":[{"award-number":["23K07906"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To explore the relationship between physique and immunological disturbances in systemic lupus erythematosus (SLE), we analyzed the clinical, immunological and transcriptomic characteristics of patients with SLE in relation to body mass index (BMI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Clinical characteristics were obtained from patient charts, and serum cytokine levels were measured. Phenotypes and transcriptomes of peripheral immune cells from patients with SLE in the ImmuNexUT database were analyzed in relation to BMI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirty-four SLE patients were included in the analysis. Fever and mucocutaneous symptoms were commonly observed in SLE patients with a low BMI. BMI was negatively correlated with the SLE disease activity (SLEDAI)-2K scores. Multiple regression analysis revealed that BMI was an independent explanatory variable for SLEDAI-2K scores, irrespective of anti-dsDNA antibody or complement levels. Although serum interferon (IFN)-alpha and IFN-gamma levels were negatively associated with BMI, causal mediation analysis showed that BMI had a direct effect on SLEDAI-2K scores, independent of IFN-alpha levels. Immunophenotyping indicated that BMI was primarily correlated with T cell subsets. BMI-related gene expression was mainly enriched in the regulatory T cells and B cell subsets. BMI was negatively correlated with several cellular metabolic pathways, including glucose metabolism-related pathways in Th1 and effector memory CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells, but not with IFN signaling.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We characterized the clinical, immunological and transcriptomic profiles of SLE patients with varying BMI. As low BMI was identified as an independent parameter for explaining disease activity, cachexia is considered one of the systemic symptoms of active SLE. Additionally, BMI influenced the phenotypic and transcriptomic alterations of acquired immune cells, independent of IFN signaling. These findings provide insights into the pathogenesis of SLE.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1503559","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:20:40Z","timestamp":1739838040000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Body weight in systemic lupus erythematosus is associated with disease activity and the adaptive immune system, independent of type I IFN"],"prefix":"10.3389","volume":"16","author":[{"given":"Hiroyuki","family":"Teruya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Shoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Itamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Tsuchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohisa","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keishi","family":"Fujio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra1100359","article-title":"Systemic lupus erythematosus","volume":"365","author":"Tsokos","year":"2011","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.39","article-title":"Systemic lupus erythematosus","volume":"2","author":"Kaul","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/roac140","article-title":"Interferons and systemic lupus erythematosus: pathogenesis, clinical features, and treatments in interferon-driven disease","volume":"33","author":"Tanaka","year":"2023","journal-title":"Mod Rheumatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1136\/ard-2022-223741","article-title":"Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets","volume":"82","author":"Crow","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2018-000270","article-title":"Interferon pathway in Sle: one key to unlocking the mystery of the disease","volume":"6","author":"R\u00f6nnblom","year":"2019","journal-title":"Lupus Sci Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-225445","article-title":"Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials","volume":"83","author":"Baker","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-023-00932-2","article-title":"Emerging mechanisms of obesity-associated immune dysfunction","volume":"20","author":"Shaikh","year":"2024","journal-title":"Nat Rev Endocrinol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/nri2921","article-title":"Adipokines in inflammation and metabolic disease","volume":"11","author":"Ouchi","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2018.00640","article-title":"Obesity, fat mass and immune system: role for leptin","volume":"9","author":"Francisco","year":"2018","journal-title":"Front Physiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/JCI92035","article-title":"Inflammatory mechanisms linking obesity and metabolic disease","volume":"127","author":"Saltiel","year":"2017","journal-title":"J Clin Invest"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04536-0","article-title":"Obesity alters pathology and treatment response in inflammatory disease","volume":"604","author":"Bapat","year":"2022","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1056\/NEJMp2021264","article-title":"Covid-19 and disparities in nutrition and obesity","volume":"383","author":"Belanger","year":"2020","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.649359","article-title":"Covid-19 severity in obesity: leptin and inflammatory cytokine interplay in the link between high morbidity and mortality","volume":"12","author":"Maurya","year":"2021","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13075-017-1308-y","article-title":"Increased serum concentrations of Il-1 Beta, Il-21 and Th17 cells in overweight patients with rheumatoid arthritis","volume":"19","author":"Shoda","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1038\/s41467-020-16571-4","article-title":"Type I interferon sensing unlocks dormant adipocyte inflammatory potential","volume":"11","author":"Chan","year":"2020","journal-title":"Nat Commun"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2012.04.019","article-title":"Decreased interferon-\u03b1 and interferon-\u03b2 Production in obesity and expression of suppressor of cytokine signaling","volume":"29","author":"Teran-Cabanillas","year":"2013","journal-title":"Nutrition"},{"key":"B19","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s10753-016-0452-x","article-title":"Role of leptin and socs3 in inhibiting the type I interferon response during obesity","volume":"40","author":"Ter\u00e1n-Cabanillas","year":"2017","journal-title":"Inflammation"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24395","article-title":"Cachexia in systemic lupus erythematosus: risk factors and relation to disease activity and damage","volume":"73","author":"Stojan","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s10067-018-4336-3","article-title":"The impact of obesity on sle disease activity: findings from the southern California lupus registry (Scolr)","volume":"38","author":"Teh","year":"2019","journal-title":"Clin Rheumatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1177\/09612033231220726","article-title":"Patients with systemic lupus erythematosus who are underweight have distinct disease characteristics","volume":"33","author":"Oh Chan","year":"2024","journal-title":"Lupus"},{"key":"B23","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1016\/j.cell.2021.03.056","article-title":"Dynamic landscape of immune cell-specific gene regulation in immune-mediated diseases","volume":"184","author":"Ota","year":"2021","journal-title":"Cell"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/J.CELL.2022.07.021","article-title":"Distinct transcriptome architectures underlying lupus establishment and exacerbation","volume":"185","author":"Nakano","year":"2022","journal-title":"Cell"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/art.34473","article-title":"Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/art.40930","article-title":"2019 European league against rheumatism\/American college of rheumatology classification criteria for systemic lupus erythematosus","volume":"71","author":"Aringer","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B27","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J Rheumatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1039\/c5mb00663e","article-title":"Reactomepa: an R\/bioconductor package for reactome pathway analysis and visualization","volume":"12","author":"Yu","year":"2016","journal-title":"Mol Biosyst"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0316","article-title":"Spatiotemporal immune landscape of colorectal cancer liver metastasis at single-cell level","volume":"12","author":"Wu","year":"2022","journal-title":"Cancer Discovery"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-7","article-title":"Gsva: gene set variation analysis for microarray and Rna-Seq data","volume":"14","author":"H\u00e4nzelmann","year":"2013","journal-title":"BMC Bioinf"},{"key":"B31","doi-asserted-by":"publisher","first-page":"keae158","DOI":"10.1093\/rheumatology\/keae158","article-title":"Machine learning-driven immunophenotypic stratification of mixed connective tissue disease corroborating the clinical heterogeneity","volume":"13","author":"Izuka","year":"2024","journal-title":"Rheumatol (Oxford)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1000367","article-title":"Body-mass index and mortality among 1.46 million white adults","volume":"363","author":"Berrington de Gonzalez","year":"2010","journal-title":"N Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v059.i05","article-title":"Mediation: rpackage for causal mediation analysis","volume":"59","author":"Tingley","year":"2014","journal-title":"J Stat Softw"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214502","article-title":"Derivation and validation of the Sle disease activity score (Sle-das): A new sle continuous measure with high sensitivity for changes in disease activity","volume":"78","author":"Jesus","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/art.24803","article-title":"Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: A validation study","volume":"60","author":"Bauer","year":"2009","journal-title":"Arthritis Rheum"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0287753","article-title":"Impact of overweight and obesity on disease activity and remission in systemic lupus erythematosus: A systematic review and meta-analysis protocol","volume":"18","author":"Medeiros","year":"2023","journal-title":"PLoS One"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2005.00637.x","article-title":"Weight loss during pegylated interferon and ribavirin treatment of chronic hepatitis C","volume":"12","author":"Seyam","year":"2005","journal-title":"J Viral Hepat"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2009.04057.x","article-title":"Interferon signature gene expression is correlated with autoantibody profiles in patients with incomplete lupus syndromes","volume":"159","author":"Li","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"4462","DOI":"10.1038\/s41598-020-60563-9","article-title":"Using the circulating proteome to assess type I interferon activity in systemic lupus erythematosus","volume":"10","author":"Smith","year":"2020","journal-title":"Sci Rep"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00624-w","article-title":"The interplay of immunology and cachexia in infection and cancer","volume":"22","author":"Baazim","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0397-y","article-title":"Cd8+ T cells induce cachexia during chronic viral infection","volume":"20","author":"Baazim","year":"2019","journal-title":"Nat Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0800928105","article-title":"T cell receptor signaling controls Foxp3 expression via Pi3k, Akt, and Mtor","volume":"105","author":"Sauer","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0120-4","article-title":"Regulatory T cells in autoimmune disease","volume":"19","author":"Dominguez-Villar","year":"2018","journal-title":"Nat Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1503559\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:20:43Z","timestamp":1739838043000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1503559\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,18]]},"references-count":43,"alternative-id":["10.3389\/fimmu.2025.1503559"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1503559","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,18]]},"article-number":"1503559"}}